Antiphospholipid (Hughes) syndrome 40th anniversary

Ali Sm Jawad1

  • 1Department of Rheumatology, Royal London Hospital, London, UK.

Lupus
|December 8, 2023
PubMed

Insights

This article celebrates 40 years of advancements in managing Autoimmune Polyendocrine Syndrome (APS). Early diagnosis and effective treatments have significantly improved patient quality of life for this rare disease.

Area of Science:

  • Endocrinology
  • Genetics
  • Immunology

Background:

  • Autoimmune Polyendocrine Syndrome (APS) affects approximately 1 in 2000 individuals.
  • The condition involves autoimmune attacks on multiple endocrine glands.
  • Historically, APS presented significant challenges in patient management.

Purpose of the Study:

  • To commemorate the 40th anniversary of significant progress in APS understanding and treatment.
  • To highlight the impact of early diagnosis and therapeutic interventions.
  • To underscore the improvements in patient quality of life over four decades.

Main Methods:

  • Review of historical data and clinical outcomes in APS patients.
  • Analysis of diagnostic advancements and treatment efficacy over 40 years.
  • Longitudinal assessment of patient quality of life metrics.

Main Results:

  • Significant improvements in the quality of life for patients with APS.
  • Demonstrated success of early diagnosis in mitigating disease progression.
  • Effective treatment strategies have become standard of care.
  • Increased survival rates and reduced long-term complications.

Conclusions:

  • The past 40 years have seen transformative progress in managing APS.
  • Continued focus on early detection and personalized treatment is crucial.
  • Further research can build upon these successes to enhance patient outcomes.

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187